Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors

No AccessJournal of UrologyAdult Urology1 Nov 2016Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors Jiajun Wang, Li Liu, Yang Qu, Wei Xi, Yu Xia, Qi Bai, Ying Xiong, Qilai Long, Jiejie Xu, and Jianming Guo Jiajun WangJiajun Wang Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China Equal study contribution. More articles by this author , Li LiuLi Liu Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China Equal study contribution. More articles by this author , Yang QuYang Qu Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China Equal study contribution. More articles by this author , Wei XiWei Xi Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author , Yu XiaYu Xia Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author , Qi BaiQi Bai Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author , Ying XiongYing Xiong Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author , Qilai LongQilai Long Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author , Jiejie XuJiejie Xu Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China More articles by this author , and Jianming GuoJianming Guo Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.06.010AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Mutations of SETD2 occur in 3% to 16% of clear cell renal cell carcinoma cases. Previous studies identified an association between SETD2 mutation and prognosis of patients with nonmetastatic clear cell renal cell carcinoma. In this study we explored the prognostic and predictive value of SETD2 expression in patients with metastatic renal cell carcinoma treated with targeted therapy. Materials and Methods: We retrospectively enrolled 138 patients with metastatic renal cell carcinoma treated with sunitinib or sorafenib at a single institution from 2007 to 2014. SETD2 expression was assessed by immunohistochemistry on tissue microarrays. Results: After excluding those patients with loss of followup or unavailable tissue samples, 111 were included in the study. Low SETD2 expression was associated with reduced overall survival (p <0.001) and progression-free survival (p=0.001). After adjustment for histological type, Heng risk group and drugs used for targeted therapy, SETD2 was defined as an independent prognostic marker for overall survival (HR 2.535 [95% CI 1.429–4.497], p=0.001) and progression-free survival (HR 1.755 [95% CI 1.031–2.988], p=0.038). Its prognostic value for overall survival was more predominant in patients with clear cell renal cell carcinoma (p <0.001) or patients in the intermediate risk group of Heng risk criteria (p <0.001), while its predictive value for progression-free survival was more predominant in patients treated with sorafenib (p <0.001). SETD2 could also be combined with the Heng risk model for better overall survival prediction. Conclusions: SETD2 is a potential prognostic biomarker for overall survival and progression-free survival prediction in patients with metastatic renal cell carcinoma receiving targeted therapy. However, it remains to be seen whether this is generalizable to other ethnicities and prospective external validation is required. References 1 : Cancer statistics, 2015. CA Cancer J Clin2015; 65: 5. Google Scholar 2 : Renal-cell carcinoma. N Engl J Med2005; 353: 2477. Google Scholar 3 : Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol2009; 27: 5794. Google Scholar 4 : External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol2013; 14: 141. Google Scholar 5 : Advances in renal neoplasia: recommendations from the 2012 International Society of Urological Pathology Consensus Conference. Urology2014; 83: 969. Google Scholar 6 : Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol2010; 11: 571. Google Scholar 7 : VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol2008; 10: 361. Google Scholar 8 : BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn2015; 15: 1201. Google Scholar 9 : The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell2013; 153: 590. Google Scholar 10 : SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife2014; 3: e2482. Google Scholar 11 : Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol2012; 13: 115. Google Scholar 12 : Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature2011; 469: 539. Google Scholar 13 : Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature2013; 499: 43. Google Scholar 14 : Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature2010; 463: 360. Google Scholar 15 : Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer2014; 53: 38. Google Scholar 16 : Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res2013; 19: 3259. Google Scholar 17 : Decreased expression of SETD2 predicts unfavorable prognosis in patients with nonmetastatic clear-cell renal cell carcinoma. Medicine (Baltimore)2015; 94: e2004. Google Scholar 18 : High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene2016; 35: 1565. Google Scholar 19 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009; 45: 228. Google Scholar 20 : Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol1982; 6: 655. Crossref, Medline, Google Scholar 21 : The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol2010; 17: 1471. Google Scholar 22 : Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res2011; 71: 7547. Google Scholar 23 : X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res2004; 10: 7252. Google Scholar 24 : Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature2015; 520: 243. Google Scholar 25 : SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep2014; 7: 2006. Google Scholar 26 : SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene2015; 34: 5699. Google Scholar © 2016 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 196Issue 5November 2016Page: 1363-1370Supplementary Materials Advertisement Copyright & Permissions© 2016 by American Urological Association Education and Research, Inc.Keywordsbiomarkerssurvivaldisease-free survivalneoplasm metastasisrenal cellcarcinomaMetricsAuthor Information Jiajun Wang Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China Equal study contribution. More articles by this author Li Liu Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China Equal study contribution. More articles by this author Yang Qu Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China Equal study contribution. More articles by this author Wei Xi Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author Yu Xia Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author Qi Bai Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author Ying Xiong Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author Qilai Long Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author Jiejie Xu Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China More articles by this author Jianming Guo Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China More articles by this author Expand All Advertisement PDF downloadLoading ...